EUFOREA consensus on biologics for CRSwNP with or without asthma

Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of pati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Allergy (Copenhagen) Jg. 74; H. 12; S. 2312 - 2319
Hauptverfasser:	Fokkens, Wytske J., Lund, Valerie, Bachert, Claus, Mullol, Joaquim, Bjermer, Leif, Bousquet, Jean, Canonica, Giorgio W., Deneyer, Lauren, Desrosiers, Martin, Diamant, Zuzana, Han, Joseph, Heffler, Enrico, Hopkins, Claire, Jankowski, Roger, Joos, Guy, Knill, Andrew, Lee, Jivianne, Lee, Stella E., Mariën, Gert, Pugin, Benoit, Senior, Brent, Seys, Sven F., Hellings, Peter W.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Denmark Blackwell Publishing Ltd 01.12.2019 Wiley John Wiley and Sons Inc
Schlagworte:	Allergies Allergology Asthma Asthma - complications Biological products Biological Products - administration & dosage Biological Products - adverse effects Biological Products - therapeutic use biologics Chronic Disease chronic rhinosinusitis Clinical Decision-Making Clinical Medicine Comorbidity Disease Management Health Services Needs and Demand Human health and pathology Humans Immunoglobulin E Immunology Immunotherapy Interleukin 5 Klinisk medicin Life Sciences Lungmedicin och allergi Medical and Health Sciences Medicin och hälsovetenskap Mucosa nasal polyps Nasal Polyps - complications Polyps Pulmonology and respiratory tract Respiratory diseases Respiratory Medicine and Allergy Respiratory tract diseases Review Reviews Rhinitis Rhinitis - complications Rhinitis - drug therapy Rhinosinusitis Sinusitis Sinusitis - complications Sinusitis - drug therapy Treatment Outcome type 2 inflammation chronic rhinosinusitis nasal polyps asthma biologics type 2 inflammation
ISSN:	0105-4538, 1398-9995, 1398-9995
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!